



PATENT
Docket No. 11245/46605

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: WAKSAL, Harlan W.

Application No.: (Unassigned)

Examiner: Hunt, Jennifer (Anticipated)

Filing Date: November 30, 2001

Art Unit: 1642 (Anticipated)

For: TREATMENT OF
REFRACTORY HUMAN
TUMORS WITH
EPIDERMAL GROWTH
FACTOR RECEPTOR
ANTAGONISTS

RECEIVED
JAN 24 2002
OFFICE OF PETITIONS

PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

Prior to examination of the present application, please enter the following amendments
and consider the following remarks.

AMENDMENTS


In the Specification:

At page 7, ll. 7-11, please replace the original paragraph with the following
paragraph:

The growth of refractory tumors is sufficiently inhibited in the patient
to prevent or reduce the progression of the cancer (i.e. growth, invasiveness,
metastasis, and/or recurrence). The EGFR antagonists of the present
invention can be cytostatic or inhibit the growth of the refractory tumor.
Preferably, the EGFR antagonist is cytolytic or destroys the tumor.

01/24/2002 SFELEKE1 00000099 110600 09996954

01 FC:103 72.00 CH



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**PRELIMINARY AMENDMENT
TRANSMITTAL LETTER**

Docket Number
11245/46605

Application Number
09/996,954

Filing Date
November 30, 2001

Examiner

Art Unit

Invention Title
**TREATMENT OF REFRACTORY HUMAN
TUMORS WITH EPIDERMAL GROWTH
FACTOR RECEPTOR ANTAGONISTS**

Inventor(s)
Harlan W. WAKSAL

RECEIVED
JAN 24 2002
OFFICE OF PETITIONS

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

Date: December 21, 2001

Reg. No. 46,885

Signature: Kathryn M. Lumb

Kathryn M. Lumb

Transmitted herewith for filing in the above-identified patent application is the following:

1. Preliminary Amendment
2. Change in Small Entity Status
3. The filing fee has been calculated as shown below after entry of the Preliminary Amendment:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT NUMBER EXTRA	RATE (\$)	FEE (\$)
TOTAL CLAIMS	37	minus	33	4	18.00	72.00
INDEPENDENT CLAIMS	1	minus	3	0	84.00	0.00
MULTIPLE DEPENDENT CLAIM ADDED					140.00	0.00
				TOTAL		72.00

4. Please charge the required additional claims fee of **\$72.00** to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**.
5. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**:

- A. Any additional filing fees required under 37 C.F.R. § 1.16;
- B. Any additional patent application processing fees under 37 C.F.R. § 1.17;
- C. Any additional patent issue fees under 37 C.F.R. § 1.18;
- D. Any additional document supply fees under 37 C.F.R. § 1.19;
- E. Any additional post-patent processing fees under 37 C.F.R. § 1.20; or
- F. Any additional miscellaneous fees under 37 C.F.R. § 1.21.

6. A duplicate copy of this letter is enclosed.

Dated: December 21, 2001

By: Kathryn M. Lumb
Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)